Chien PF, Arnott N, Gordon A, Owen P, Khan KS How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG. 2000 Feb;107(2):196-208. Review.
Duley L, Henderson-Smart DJ, Knight M, King JF Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2004;(1):CD004659. Review. Update in: Cochrane Database Syst Rev. 2007;(2):CD004659.
Duley L, Henderson-Smart DJ, Meher S, King JF Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. Review. Update in: Cochrane Database Syst Rev. 2019 Oct 30;2019(10):.
Ebrashy A, Ibrahim M, Marzook A, Yousef D Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005 Oct;46(5):826-31.
Heyborne KD Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol. 2000 Sep;183(3):523-8. Review.
Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009 Apr;40(4):1176-80. doi: 10.1161/STROKEAHA.108.538025. Epub 2009 Mar 5.
Landolfi R, Cipriani MC, Novarese L Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19(3):617-33. Review.
Li DK, Liu L, Odouli R Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368.
Loe SM, Sanchez-Ramos L, Kaunitz AM Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol. 2005 Jul;106(1):173-9. Review.
March of Dimes, Save the Children, WHO (2012). Born Too Soon: The Global Action Report on Preterm Birth. (M. V. K. CP Howson JE Lawn., Ed.). Geneva: World Health Organization.
Mathews, T J., Menacker, F., & MacDorman, M. F. (2004). Infant mortality statistics from the 2002 period: linked birth/infant death data set. National Vital Statistics Reports : From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 53(10), 1-29. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15622996
RE, B , & AS, B. (2006). Preterm Birth: Causes, Consequences, and Prevention. (I. of M. of the Academies, Ed.). Washington, DC: The National Academies Press.
Saigal S, Doyle LW An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008 Jan 19;371(9608):261-9. doi: 10.1016/S0140-6736(08)60136-1. Review.
Smith GC, Shah I, Pell JP, Crossley JA, Dobbie R Maternal obesity in early pregnancy and risk of spontaneous and elective preterm deliveries: a retrospective cohort study. Am J Public Health. 2007 Jan;97(1):157-62. Epub 2006 Nov 30.
Smith GC Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol. 2001 Feb;184(3):489-96.
Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002 Feb;109(2):161-7.
Vainio M, Riutta A, Koivisto AM, Mäenpää J Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand. 2004 Dec;83(12):1119-23.
Vane JR, Botting RM The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. Review.
Vermillion ST, Robinson CJ Antiprostaglandin drugs. Obstet Gynecol Clin North Am. 2005 Sep;32(3):501-17. Review.
Werler MM, Sheehan JE, Mitchell AA Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002 Jan 1;155(1):26-31.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.